Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
Nov 6 (Reuters) -Charles River Laboratories CRL.N raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services.
The company's shares were up 14% to $215.06 before the bell on Wednesday.
Contract research organizations have been seeing reduced spending from biotech clients since the past year, but recent interest rate cuts could improve the funding environment for biotechs.
Overall demand trends from larger drugmakers do not appear to have deteriorated further, Charles River CEO James Foster said.
In the second quarter, the company said bookings and proposals from larger drugmakers declined as they reprioritized development pipelines due to potential impacts from the U.S. government's drug price negotiation program.
Funding for smaller biotech firms has improved in 2024 and demand appears to be showing early signs of stabilization, Foster said, adding that the factors resulted in a slight improvement in orders and cancellations for Charles River's services.
Charles River now expects 2024 adjusted profit between $10.10 and $10.30 per share, compared with its prior forecast range of $9.90 to $10.20 per share.
The company also forecast full-year revenue to now decrease 2% to 3%, versus previous expectations of it falling 2.5% to 4.5%.
Charles River's third-quarter revenue fell 1.6% to $1.01 billion, but beat the average analyst estimate of $976 million, according to data compiled by LSEG.
The company's drug manufacturing and research model services segments, which are smaller in size, reported revenue growth of 12% and 5.9%, respectively, helping the company offset a decline in its main business.
On an adjusted basis, Charles River earned $2.59 per share, beating estimates of $2.43.
Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
